ES2221212T5 - Metodos para la modulacion de la neovascularizacion y/o el crecimiento de arterias colaterales y/o de otras arterias a partir de conexiones arteriolares preexistentes. - Google Patents

Metodos para la modulacion de la neovascularizacion y/o el crecimiento de arterias colaterales y/o de otras arterias a partir de conexiones arteriolares preexistentes. Download PDF

Info

Publication number
ES2221212T5
ES2221212T5 ES98951483T ES98951483T ES2221212T5 ES 2221212 T5 ES2221212 T5 ES 2221212T5 ES 98951483 T ES98951483 T ES 98951483T ES 98951483 T ES98951483 T ES 98951483T ES 2221212 T5 ES2221212 T5 ES 2221212T5
Authority
ES
Spain
Prior art keywords
csf
arteries
collateral
growth
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98951483T
Other languages
English (en)
Spanish (es)
Other versions
ES2221212T3 (es
Inventor
Ivo R. Buschmann
Wolfgang Schaper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227431&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2221212(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of ES2221212T3 publication Critical patent/ES2221212T3/es
Application granted granted Critical
Publication of ES2221212T5 publication Critical patent/ES2221212T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Photolithography (AREA)
  • Peptides Or Proteins (AREA)
ES98951483T 1997-10-02 1998-10-01 Metodos para la modulacion de la neovascularizacion y/o el crecimiento de arterias colaterales y/o de otras arterias a partir de conexiones arteriolares preexistentes. Expired - Lifetime ES2221212T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97117155 1997-10-02
EP97117155 1997-10-02
EP98951483A EP1019082B2 (en) 1997-10-02 1998-10-01 Use of a colony stimulating factor (csf) for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections
PCT/EP1998/006233 WO1999017798A1 (en) 1997-10-02 1998-10-01 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections

Publications (2)

Publication Number Publication Date
ES2221212T3 ES2221212T3 (es) 2004-12-16
ES2221212T5 true ES2221212T5 (es) 2008-12-01

Family

ID=8227431

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98951483T Expired - Lifetime ES2221212T5 (es) 1997-10-02 1998-10-01 Metodos para la modulacion de la neovascularizacion y/o el crecimiento de arterias colaterales y/o de otras arterias a partir de conexiones arteriolares preexistentes.

Country Status (9)

Country Link
US (4) US7507705B2 (https=)
EP (1) EP1019082B2 (https=)
JP (2) JP4891477B2 (https=)
AT (1) ATE257392T1 (https=)
CA (1) CA2304354A1 (https=)
DE (1) DE69821011T3 (https=)
DK (1) DK1019082T4 (https=)
ES (1) ES2221212T5 (https=)
WO (1) WO1999017798A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507705B2 (en) 1997-10-02 2009-03-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
AU4544600A (en) * 1999-04-06 2000-10-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof
US20020034501A1 (en) * 2000-05-18 2002-03-21 Robert Pawliuk Methods and compositions for promoting angiogenesis using monocytes
MXPA02012067A (es) * 2000-06-05 2004-08-19 Univ Columbia Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico.
DE10033219A1 (de) * 2000-07-07 2002-01-24 Univ Heidelberg Neuroprotektive Wirkung von Granulocyten-Colony Stimmulierendem Faktor (G-CSF)
WO2002022163A1 (en) 2000-09-13 2002-03-21 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
FR2834898B1 (fr) * 2002-01-18 2005-06-10 Didier Pourquier Nouvelle application therapeutique du g-csf, du gm-csf et du scf
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
CA2509618A1 (en) * 2002-12-13 2004-07-01 Hisayoshi Fujiwara Pharmaceutical compositions for treating non-ischemic heart failure
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7166458B2 (en) * 2003-01-07 2007-01-23 Bio Tex, Inc. Assay and method for analyte sensing by detecting efficiency of radiation conversion
EP1527785A1 (en) * 2003-10-27 2005-05-04 Ludwig-Maximilians-Universität München Use of G-CSF for treating ischemia
AU2004283609B2 (en) * 2003-10-27 2010-05-20 Chugai Seiyaku Kabushiki Kaisha G-CSF-containing substance for fibroblast recruitment and G-CSF-containing therapeutic agent for wound healing
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
KR20060124610A (ko) * 2003-11-06 2006-12-05 셀진 코포레이션 석면-관련된 질환 또는 장애를 치료 및 관리하기 위하여ｊｎｋ 억제제를 사용하는 방법 및 이 물질을 포함하는조성물
WO2005084702A1 (ja) * 2004-03-02 2005-09-15 Hokkaido Technology Licensing Office Co., Ltd. 臓器線維症予防・治療剤
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
WO2006096931A1 (en) * 2005-03-18 2006-09-21 The University Of Queensland Renal repair and regeneration
CN101534851B (zh) 2006-09-15 2015-03-04 肯塔控股有限公司 促进器官发育的方法和组合物
PL2188313T3 (pl) 2007-08-21 2018-04-30 Amgen, Inc. Białka wiążące ludzki antygen c-fms
EP2036571A1 (de) 2007-09-13 2009-03-18 Sygnis Bioscience GmbH & Co. KG Verwendung von G-CSF für die Behandlung von Schlaganfall
RU2376995C1 (ru) * 2008-09-26 2009-12-27 Евгений Владимирович Пыхтин Способ лечения ишемии нижних конечностей
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
DK2734547T3 (en) 2011-07-18 2017-04-03 Univ Melbourne USE OF C-FMS ANTIBODIES
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
EA031471B1 (ru) 2013-04-12 2019-01-31 МорфоСис АГ Антитела, направленные на m-csf
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
US12290564B2 (en) * 2017-05-18 2025-05-06 Renovorx, Inc. Methods and apparatuses for treating tumors
US12293315B2 (en) 2021-10-27 2025-05-06 Express Scripts Strategic Development, Inc. System and method for load balancing carrier devices among stations in a packing system
US12293330B2 (en) 2021-10-27 2025-05-06 Express Scripts Strategic Development, Inc. Product packing system and method

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3629640A1 (de) 1986-08-30 1988-03-03 Behringwerke Ag Verwendung monoklonaler antikoerper zur therapie von tumoren
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5047504A (en) * 1987-04-28 1991-09-10 Amgen, Inc. Method for purifying granulocyte-macrophage colony stimulating factor
MC2115A1 (fr) 1987-12-15 1991-07-05 Gene Shears Pty Ltd Ribozynes
US4980281A (en) 1988-02-10 1990-12-25 Housey Gerard M Method of screening for protein inhibitors and activators
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
JPH05506673A (ja) 1991-02-22 1993-09-30 アムジエン・インコーポレーテツド 迅速な創傷の治癒を促進するためのｇｍ―ｃｓｆ及びｇ―ｃｓｆの使用
US5466781A (en) * 1991-05-24 1995-11-14 Chiron Therapeutics Process for purifying bacterially produced M-CSF
JP3954005B2 (ja) 1991-12-26 2007-08-08 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
JP3954004B2 (ja) 1991-12-26 2007-08-08 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
JP3537151B2 (ja) 1991-12-26 2004-06-14 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
JPH07188048A (ja) 1993-12-27 1995-07-25 Green Cross Corp:The 血管内膜肥厚改善剤
AUPM375094A0 (en) 1994-02-08 1994-03-03 Ludwig Institute For Cancer Research Cytokine receptor interactive molecules and methods for assaying cytokine function
US7153827B1 (en) * 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
WO1998033917A1 (en) 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5570372A (en) 1995-11-08 1996-10-29 Siemens Rolm Communications Inc. Multimedia communications with system-dependent adaptive delays
KR100695590B1 (ko) * 1996-11-01 2007-03-14 아크 테라퓨틱스 리미티드 산화질소 또는 프로스타시클린 생산을 자극하는 약제의 치료학적 용도 및 전달 기구
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
WO1998044953A1 (en) 1997-04-04 1998-10-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
US7507705B2 (en) * 1997-10-02 2009-03-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
AU4544600A (en) 1999-04-06 2000-10-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof
DE10033219A1 (de) 2000-07-07 2002-01-24 Univ Heidelberg Neuroprotektive Wirkung von Granulocyten-Colony Stimmulierendem Faktor (G-CSF)
MXPA03002045A (es) * 2000-09-08 2003-07-24 Amgen Inc Composiciones analogas de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
WO2002022163A1 (en) 2000-09-13 2002-03-21 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
US6544543B1 (en) * 2000-12-27 2003-04-08 Advanced Cardiovascular Systems, Inc. Periodic constriction of vessels to treat ischemic tissue
DE60220894T2 (de) 2001-03-12 2008-02-28 Institute Of Gene And Brain Science Verwendung von interleukin-12 zur behandlung von nervenschäden
US20020131959A1 (en) * 2001-03-14 2002-09-19 Ivo Buschmann Means and methods for the modulation of arteriogenesis
US20020198150A1 (en) 2001-06-07 2002-12-26 Ayelet Chajut Methods of using colony stimulating factors in the treatment of tissue damage and ischemia
FR2834898B1 (fr) 2002-01-18 2005-06-10 Didier Pourquier Nouvelle application therapeutique du g-csf, du gm-csf et du scf
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US20060142102A1 (en) * 2004-12-23 2006-06-29 Mijo Radocaj Pulley assembly
US7569545B2 (en) * 2005-05-20 2009-08-04 Academia Sinica Methods of increasing neurotrophic factor expression
US7618938B2 (en) * 2007-02-07 2009-11-17 Academia Sinica Treating cerebrovascular diseases with erythropoietin and granulocyte-colony stimulating factor jointly
WO2008137571A1 (en) * 2007-05-01 2008-11-13 Florida Atlantic University Methods of treating neurodegenerative diseases

Also Published As

Publication number Publication date
US20030147862A1 (en) 2003-08-07
EP1019082B1 (en) 2004-01-07
ES2221212T3 (es) 2004-12-16
DK1019082T4 (da) 2008-10-27
ATE257392T1 (de) 2004-01-15
JP2009132744A (ja) 2009-06-18
DK1019082T3 (da) 2004-05-10
WO1999017798A1 (en) 1999-04-15
DE69821011D1 (de) 2004-02-12
CA2304354A1 (en) 1999-04-15
DE69821011T2 (de) 2004-11-18
JP4891477B2 (ja) 2012-03-07
EP1019082B2 (en) 2008-06-04
US7507705B2 (en) 2009-03-24
US20090093413A1 (en) 2009-04-09
US20090191146A1 (en) 2009-07-30
JP2001518517A (ja) 2001-10-16
US8101188B2 (en) 2012-01-24
US20090093412A1 (en) 2009-04-09
EP1019082A1 (en) 2000-07-19
DE69821011T3 (de) 2009-01-08

Similar Documents

Publication Publication Date Title
ES2221212T5 (es) Metodos para la modulacion de la neovascularizacion y/o el crecimiento de arterias colaterales y/o de otras arterias a partir de conexiones arteriolares preexistentes.
Weber et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma
Weber et al. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma
ES2609094T3 (es) Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante
Takagi et al. Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization
ES2274549T3 (es) Compuestos para la inhibicion de la angiogenesis por terapia de genes .
ES2234818T3 (es) Procedimiento para tratar canceres que expresan el factor de crecimiento endotelial d.
JP2009148293A (ja) 血管内皮増殖因子のペプチドアンタゴニスト
CA2802143C (en) Sparc encoding polynucleotide as a cancer therapy sensitizer
EP0969877B1 (en) Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
US20050112061A1 (en) Use of a VEGF antagonist in combination with radiation therapy
US20050196340A1 (en) Use of a VEGF antagonist in combination with radiation therapy
JP2003528813A (ja) 遺伝子治療による固体腫瘍及び転移の治療方法
Kinoshita et al. A gene delivery system with a human artificial chromosome vector based on migration of mesenchymal stem cells towards human glioblastoma HTB14 cells
Lukas et al. A survey of the neuro-oncology landscape
WO1999061039A2 (en) Novel composition for modulating ischemic cell death
US20020131959A1 (en) Means and methods for the modulation of arteriogenesis
EA022915B1 (ru) Способы лечения острого миелоидного лейкоза и миелодиспластического синдрома
US20240148765A1 (en) Compositions and methods for treating and/or preventing therapy-related cardiomyopathy associated with neutrophil infiltration
ES2326978T3 (es) Procedimiento de tratamiento del carcinoma hepatocelular.
VENGLER et al. SIBERIAN JOURNAL OF ONCOLOGY
KR101802316B1 (ko) ｍｉＲＮＡ―３０의 방사선 민감성 조절 용도
Kirsch et al. Endogenous growth inhibition of glioma